Ranexa (ranolazine) Extended-release Tablets 

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) January 2016 ADVERSE REACTIONS Post Marketing Experience Metabolism and Nutrition Disorders Cases of hypoglycemia have been...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts